Guardant Health (NASDAQ:GH) Given New $53.00 Price Target at Stifel Nicolaus

Guardant Health (NASDAQ:GH) had its target price upped by research analysts at Stifel Nicolaus from $45.00 to $53.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ target price points to a potential upside of 16.01% from the company’s current price.

Several other research analysts also recently commented on GH. Sanford C. Bernstein dropped their price objective on shares of Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a report on Wednesday, October 30th. Barclays began coverage on Guardant Health in a report on Thursday, January 23rd. They set an “overweight” rating and a $60.00 price target on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Guardant Health from $48.00 to $50.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. The Goldman Sachs Group increased their target price on shares of Guardant Health from $36.00 to $49.00 and gave the company a “buy” rating in a research note on Tuesday, January 28th. Finally, Guggenheim reissued a “buy” rating on shares of Guardant Health in a research note on Wednesday, January 22nd. Seventeen research analysts have rated the stock with a buy rating, According to data from MarketBeat, Guardant Health currently has an average rating of “Buy” and an average target price of $43.24.

Guardant Health Trading Down 3.6 %

NASDAQ GH opened at $45.69 on Friday. Guardant Health has a 12 month low of $15.81 and a 12 month high of $50.89. The stock has a market cap of $5.64 billion, a price-to-earnings ratio of -10.83 and a beta of 1.32. The company’s 50 day moving average is $40.03 and its two-hundred day moving average is $31.51.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The firm had revenue of $201.81 million for the quarter, compared to the consensus estimate of $192.50 million. Guardant Health had a negative net margin of 74.02% and a negative return on equity of 1,200.44%. Sell-side analysts forecast that Guardant Health will post -3.39 EPS for the current year.

Insider Transactions at Guardant Health

In other news, Director Musa Tariq sold 2,320 shares of the company’s stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $35.00, for a total value of $81,200.00. Following the sale, the director now owns 2,676 shares in the company, valued at $93,660. This represents a 46.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 2,652 shares of company stock worth $93,192 over the last 90 days. 5.50% of the stock is currently owned by company insiders.

Institutional Trading of Guardant Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. purchased a new stake in Guardant Health in the 4th quarter worth $79,000. Twinbeech Capital LP purchased a new stake in shares of Guardant Health during the fourth quarter worth $367,000. Two Sigma Advisers LP grew its holdings in shares of Guardant Health by 96.7% during the fourth quarter. Two Sigma Advisers LP now owns 2,315,600 shares of the company’s stock worth $70,742,000 after buying an additional 1,138,300 shares in the last quarter. Two Sigma Investments LP raised its position in shares of Guardant Health by 38.5% in the fourth quarter. Two Sigma Investments LP now owns 1,890,714 shares of the company’s stock valued at $57,761,000 after buying an additional 525,368 shares during the last quarter. Finally, Tema Etfs LLC purchased a new position in shares of Guardant Health in the fourth quarter worth about $1,103,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.